The liver is one of the more heavily studied organs in the fisetin literature, with more than a hundred indexed papers touching on it. That volume can look like strong evidence at a glance. It isn’t, quite: the studies are consistent in direction but almost entirely in rodents, frequently using injected fisetin at doses no supplement delivers, and none of them have been followed by a human trial. Here is what the research supports, and where it stops.
Key Takeaways
- In high-fat-diet mouse models of fatty liver, fisetin reduced liver lipid droplets, hepatocyte steatosis, and serum free fatty acids, working through the Sirt1/AMPK pathway and increased fatty acid β-oxidation.
- A 2025 study in metabolic dysfunction-associated fatty liver disease (MAFLD) mice found fisetin also improved blood glucose and lipid profile, acting partly through the GSK-3β/Nrf2/HO-1 antioxidant pathway.
- Fisetin reduced liver fibrosis in two separate injury models, alcohol-fed mice and methotrexate-injured rats, in both cases suppressing the activated hepatic stellate cells that lay down scar tissue.
- The dosing gap matters: the foundational steatosis study injected fisetin intraperitoneally, and the alcohol and methotrexate studies used 80 mg/kg and 50 mg/kg per day respectively, delivered by injection rather than by mouth.
- No human clinical trial has tested fisetin for fatty liver, liver fibrosis, or any other liver outcome.
Why the Liver Shows Up So Often in Fisetin Research
Two of fisetin’s better-characterized molecular effects happen to land squarely on liver biology. It activates AMPK and SIRT1, the pair of nutrient-sensing proteins that push cells toward burning fat rather than storing it, and it activates Nrf2, the master switch for a cell’s antioxidant defenses. Fatty liver disease is, mechanistically, a problem of too much fat storage plus oxidative stress. So researchers testing fisetin in liver models are testing a compound whose known pathways line up with the disease, which is part of why the results have been fairly consistent.
What the Fatty Liver Studies Found
The most-cited work is a 2018 study in high-fat-diet-induced obese mice. Mice given fisetin for ten weeks had less body weight and epididymal fat, fewer liver lipid droplets, less hepatocyte steatosis, lower serum free fatty acids and leptin, and significantly reduced fatty acid synthase. In liver tissue, phosphorylated AMPKα, sirt-1, and carnitine palmitoyltransferase I all increased, the signature of a liver shifting from making fat to burning it. In parallel cell work, fisetin reduced lipid accumulation and increased β-oxidation in hepatocytes challenged with oleic acid[1].
A 2025 study extended this to a MAFLD model and added a metabolic dimension. Fisetin mitigated weight gain and improved blood glucose and blood lipid disorder alongside liver steatosis. RNA sequencing showed it upregulated Glut4 and GPx3 while downregulating the inflammatory genes IL-1β and Cxcl10; in cultured human liver cells it activated GSK-3β/Nrf2/HO-1 signaling and suppressed the gluconeogenic enzymes PEPCK and G6PC[2]. In plain terms: less fat made, less glucose produced, better antioxidant capacity.
The Fibrosis Studies Are More Interesting, and More Limited
Steatosis is fat in the liver. Fibrosis is scarring, and it is what actually progresses toward cirrhosis. Two separate injury models have tested fisetin against it.
In alcohol-fed mice, fisetin at 80 mg/kg reduced ALT, AST, triglycerides, and total cholesterol, and reduced liver injury and fibrosis on staining. The mechanism traced to hepatic stellate cells, the cells that turn into collagen-producing myofibroblasts and drive scarring: fisetin suppressed their activation in a dose-dependent way, promoted SIRT1-mediated autophagy, and inhibited SphK1-mediated endoplasmic reticulum stress. When the researchers blocked SIRT1 with an inhibitor, fisetin’s effect on stellate cells was reversed, which is the kind of control experiment that makes a mechanistic claim credible[3].
In a rat model of methotrexate-induced liver fibrosis, fisetin at 50 mg/kg/day for ten days lowered TGF-β1, malondialdehyde, cytokeratin 18, thrombospondin 1, and ALT, and raised SIRT-1. Histology confirmed less hepatocyte necrosis, fibrosis, and cellular infiltration than in the untreated injured group[4]. The authors’ own conclusion is worth quoting in spirit: further investigations and clinical studies are warranted to assess translational potential. That is researcher language for “this has not been tested in people.”
The Dosing Problem Nobody Should Skip Past
Read the methods sections and a pattern appears. The 2018 steatosis study injected fisetin intraperitoneally, straight into the abdominal cavity, bypassing the digestive tract entirely. The alcohol study used 80 mg/kg. The methotrexate study used 50 mg/kg/day, also by injection. Fisetin’s oral bioavailability is poor, which is a well-established limitation of the compound and the reason researchers inject it in the first place. An injected dose and a swallowed capsule are not interchangeable, and a mouse dose does not convert to a human dose by simply multiplying body weight. Any article that reports “fisetin reverses fatty liver” without mentioning the route of administration is skipping the part that determines whether the finding applies to a supplement at all.
Where the Senescence Angle Fits
Fisetin is best known as a senolytic, and senescent cells do accumulate in aging and diseased livers. But note what the liver studies above actually measured: lipid metabolism, oxidative stress, ER stress, stellate cell activation. They mostly did not demonstrate that clearing senescent hepatocytes was the cause of the improvement. A 2024 review of fisetin as a senotherapeutic agent covers the broader case for the compound across age-related disease and notes both senolytic and senomorphic mechanisms[5], but the specific liver findings here rest on metabolic and anti-fibrotic pathways more than on senescent cell clearance. Those are different claims and it is worth keeping them separate.
Practical Takeaway
The liver research is directionally consistent across steatosis, alcohol injury, and drug-induced fibrosis, and the mechanisms are plausible and well-controlled. That is genuinely more than many supplement claims have behind them. It is still entirely preclinical, mostly injected, and at doses well above what a capsule provides. If you have fatty liver disease or elevated liver enzymes, the evidence-based interventions with human outcome data are weight loss, reduced alcohol, and management of metabolic risk factors, handled with a physician. Fisetin is an interesting research direction, not a treatment. And if you are on methotrexate or any hepatotoxic medication, do not add a supplement to the picture based on a rat study without telling your prescriber.
References
- Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cell Physiol Biochem (2018). PMID 30235452
- Effect and mechanism of fisetin against the development of metabolic dysfunction-associated fatty liver disease. Sci Rep (2025). PMID 41087497
- Fisetin Ameliorates Alcohol-Induced Liver Injury through Regulating SIRT1 and SphK1 Pathway. Am J Chin Med (2022). PMID 36266756
- Fisetin ameliorates methotrexate induced liver fibrosis. Eur Rev Med Pharmacol Sci (2024). PMID 38708470
- Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases. Mech Ageing Dev (2024). ScienceDirect
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
